ONWARD (formerly GTX Medical) is a medical technology company developing and commercializing innovative therapies to enable functional recovery for people with spinal cord injuries. Driven by its mission to restore movement, independence, and health, ONWARD builds on more than a decade of fundamental science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, delivered by proprietary implantable or external systems, is designed to deliver targeted, programmed stimulation of the spinal cord in order to restore movement and other functions in people with spinal cord injury and improve their quality of life. Both of ONWARD’s technology platforms have been awarded Breakthrough Device Designation by the FDA. ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands and the EPFL Innovation Park in Lausanne, Switzerland, with a growing U.S. presence in Boston, Massachusetts, USA.
Location: Netherlands, North Brabant, Eindhoven
Employees: 51-200
Total raised: $155.04M
Founded date: 2014
Investors 7
Date | Name | Website |
- | Verve Vent... | verve.vc |
- | Venture Ki... | venturekic... |
- | b2venture | b2venture.... |
- | VentureLab | venturelab... |
09.01.2021 | Wellington... | wellington... |
16.06.2022 | GIMV | gimv.com |
28.12.2020 | Life Scien... | lspvc.com |
Funding Rounds 3
Date | Series | Amount | Investors |
25.03.2024 | - | $21.83M | - |
21.10.2021 | IPO | $101.22M | - |
22.04.2021 | - | $32M | - |
Mentions in press and media 36
Date | Title | Description |
03.05.2024 | Avis de convocation à l’assemblée générale 2024 des actionnaires ONWARD® et propositions de résolutions | EINDHOVEN, Pays-Bas, 03 mai 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext : ONWD), société de technologie médicale à l’origine de thérapies innovantes ciblées sur la restauration du mouvement, de la fonction et de l’indépendance de... |
02.05.2024 | ONWARD® Medical Convocation of the 2024 Annual General Meeting of Shareholders and Proposed Resolutions | EINDHOVEN, the Netherlands, May 02, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people ... |
05.04.2024 | Swiss healthcare innovators tap into the US market | Basel-based startup Basilea Pharmaceutica announced the FDA approval of ZEVTERA, their antibacterial treatment of adult patients with Staphylococcus aureus bloodstream infections (bacteremia), adult patients with acute bacterial skin and s... |
26.03.2024 | ONWARD Medical Secures €20 Million for Spinal Cord Therapies | ONWARD Medical, a pioneer in spinal cord stimulation therapies, has successfully raised €20 million through a strategic offering. The company's innovative treatments aim to restore movement and independence for individuals with spinal cord ... |
25.03.2024 | ONWARD Medical Raises €20 Million | ONWARD Medical creates innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and movement disorders. The company raised €20 million in gross proceeds by way of ... |
25.03.2024 | ONWARD Medical raises EUR 20 Million for spinal cord injury products | ONWARD Medical, a company focusing on innovative spinal cord injuries and movement disorders therapies, recently raised EUR 20 million through private and public offerings. These funds will primarily support research and development activit... |
25.03.2024 | ONWARD Medical raises EUR 20 Million for spinal cord injury products | ONWARD Medical raises EUR 20 Million for spinal cord injury products 25.03.2024 16:13, Rita Longobardi linkedIn facebook twitter instagram youtube --> ONWARD Medical secures EUR 20 million in funding through private placement and public ... |
26.01.2024 | New milestones for life sciences startups | BioVersys AG is a clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of therapies for life-threatening multidrug-resistant bacterial infections and targeted microbiome modulation. The company is d... |
06.11.2023 | This spinal implant tech could restore mobility to Parkinson’s patients | People with Parkinson’s disease are being diagnosed earlier and living with the condition for longer periods as treatments evolve, but one stubborn late-arriving symptom is trouble walking. A promising new spinal implant from Swiss research... |
19.10.2023 | Global accelerators propel Swiss life sciences |
Show more